A JBS Science, com sede na Pensilvânia, disse hoje que recebeu o Bridge Award for Small Business Innovation Research IIB de US$ 3 milhões do National Cancer Institute. A empresa desenvolveu o primeiro produto de biópsia líquida, que é a triagem de DNA na urina para câncer precoce de células do fígado (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of câncer de fígado. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
A JBS disse que cooperou com James Hamilton, do Centro Médico da Universidade Johns Hopkins, e Hie-Won Hann, do Hospital Universitário Thomas, para avançar no desenvolvimento do teste de urina para câncer de fígado.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
